Skip to main content

Table 2 Meta-analysis of Huangqi injection with the changes in plasma lipid levels

From: The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials

Groups or subgroups Studies (Subjects) P Heterogeneity SMD (95% CI) P SMD
TG
 All 6 (440) <  0.001 −1.27 (− 2.53, 0.00) 0.05
 Nephrotic syndrome 4 (274) <  0.001 −1.49 (− 3.56, 0.58) 0.16
 Low-dose (<  40 mL) 2 (196) <  0.001 −3.49 (− 7.55, 0.57) 0.09
 High-dose (≥ 40 mL) 4 (244) <  0.001 −0.21 (−1.14, 0.73) 0.67
 Short-duration (<  4 weeks) 2 (160) <  0.001 −2.28 (−8.74, 4.19) 0.49
 Long-duration (≥ 4 weeks) 4 (280) <  0.01 −0.84 (−1.43, − 0.26) <  0.01
TC
 All 7 (542) <  0.001 −1.13 (−2.09, −0.16) 0.02
 Nephrotic syndrome 5 (376) <  0.001 −1.41 (−2.88, 0.07) 0.06
 Low-dose (<  40 mL) 3 (298) <  0.001 −2.13 (−3.98, −0.29) 0.02
 High-dose (≥ 40 mL) 4 (244) <  0.001 −0.40 (−1.47, 0.67) 0.47
 Short-duration (<  4 weeks) 2 (160) <  0.001 −1.98 (−7.85, 3.89) 0.51
 Long-duration (≥ 4 weeks) 5 (382) 0.03 −0.83 (−1.19, − 0.47) <  0.001
LDL-C
 All 3 (220) 0.72 −0.15 (− 0.41, 0.12) 0.28
HDL-C     
 All 3 (220) <  0.05 0.28 (−0.22, 0.77) 0.27
  1. SMD standardized mean difference, 95% CI 95% confidence interval, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol